Abstract
Pathological remodelling of astroglia represents an important component of the pathogenesis of Alzheimer's disease (AD). In AD astrocytes undergo both atrophy and reactivity; which may be specific for different stages of the disease evolution. Astroglial reactivity represents the generic defensive mechanism, and inhibition of astrogliotic response exacerbates b-amyloid pathology associated with AD. In animal models of AD astroglial reactivity is different in different brain regions, and the deficits of reactive response observed in entorhinal and prefrontal cortices may be linked to their vulnerability to AD progression. Reactive astrogliosis is linked to astroglial Ca2+ signalling, this latter being widely regarded as a mechanism of astroglial excitability. The AD pathology evolving in animal models as well as acute or chronic exposure to β-amyloid induce pathological remodelling of Ca2+ signalling toolkit in astrocytes. This remodelling modifies astroglial Ca2+ signalling and may be linked to cellular mechanisms of AD pathogenesis.
Keywords: Alzheimer's disease, astrocyte, astroglial atrophy, astrogliosis, calcium signaling, glutamate receptors, InsP3 receptors, neuroglia, β-amyloid.
Current Alzheimer Research
Title:Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease
Volume: 13 Issue: 4
Author(s): Dmitry Lim, J. J Rodríguez-Arellano, Vladimir Parpura, Robert Zorec, Fares Zeidán-Chuliá, Armando A. Genazzani and Alexei Verkhratsky
Affiliation:
Keywords: Alzheimer's disease, astrocyte, astroglial atrophy, astrogliosis, calcium signaling, glutamate receptors, InsP3 receptors, neuroglia, β-amyloid.
Abstract: Pathological remodelling of astroglia represents an important component of the pathogenesis of Alzheimer's disease (AD). In AD astrocytes undergo both atrophy and reactivity; which may be specific for different stages of the disease evolution. Astroglial reactivity represents the generic defensive mechanism, and inhibition of astrogliotic response exacerbates b-amyloid pathology associated with AD. In animal models of AD astroglial reactivity is different in different brain regions, and the deficits of reactive response observed in entorhinal and prefrontal cortices may be linked to their vulnerability to AD progression. Reactive astrogliosis is linked to astroglial Ca2+ signalling, this latter being widely regarded as a mechanism of astroglial excitability. The AD pathology evolving in animal models as well as acute or chronic exposure to β-amyloid induce pathological remodelling of Ca2+ signalling toolkit in astrocytes. This remodelling modifies astroglial Ca2+ signalling and may be linked to cellular mechanisms of AD pathogenesis.
Export Options
About this article
Cite this article as:
Lim Dmitry, Rodríguez-Arellano J J., Parpura Vladimir, Zorec Robert, Zeidán-Chuliá Fares, Genazzani A. Armando and Verkhratsky Alexei, Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116130104
DOI https://dx.doi.org/10.2174/1567205013666151116130104 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Current Advances in Gene Therapy for the Treatment of Genodermatoses
Current Gene Therapy Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease
Current Molecular Pharmacology Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Excessive Indoor Tanning as a Behavioral Addiction: A Literature Review
Current Pharmaceutical Design Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Targeting Vascular Endothelial Growth Factor in Neuroblastoma
Current Angiogenesis (Discontinued)